Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus
Clinical and Molecular Hepatology
;
: 168-176, 2014.
Article
in English
| WPRIM
| ID: wpr-119487
ABSTRACT
BACKGROUND/AIMS:
Adefovir dipivoxil (ADV) is a nucleotide analogue that is effective against lamivudine-resistant hepatitis B virus (HBV). The aim of this study was to determine the long-term clinical outcomes after ADV rescue therapy in decompensated patients infected with lamivudine-resistant HBV.METHODS:
In total, 128 patients with a decompensated state and lamivudine-resistant HBV were treated with ADV at a dosage of 10 mg/day for a median of 33 months in this multicenter cohort study.RESULTS:
Following ADV treatment, 86 (72.3%) of 119 patients experienced a decrease in Child-Pugh score of at least 2 points, and the overall end-stage liver disease score decreased from 16+/-5 to 14+/-10 (mean +/- SD, P or =2 points; P=0.001) and high mortality following ADV rescue therapy (P=0.012).CONCLUSIONS:
Three years of ADV treatment was effective and safe in decompensated patients with lamivudine-resistant HBV.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Severity of Illness Index
/
DNA, Viral
/
Adenine
/
Odds Ratio
/
Hepatitis B virus
/
Survival Rate
/
Retrospective Studies
/
Cohort Studies
/
Lamivudine
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Risk factors
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
English
Journal:
Clinical and Molecular Hepatology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS